CSIMarket
 
Qiagen N v   (NYSE: QGEN)
Other Ticker:  
 
 
Price: $45.6300 $-0.20 -0.436%
Day's High: $45.97 Week Perf: -0.8 %
Day's Low: $ 45.40 30 Day Perf: 2.15 %
Volume (M): 1,556 52 Wk High: $ 47.93
Volume (M$): $ 70,991 52 Wk Avg: $43.67
Open: $45.57 52 Wk Low: $39.03



 Market Capitalization (Millions $) 10,523
 Shares Outstanding (Millions) 231
 Employees 5,800
 Revenues (TTM) (Millions $) 1,901
 Net Income (TTM) (Millions $) 341
 Cash Flow (TTM) (Millions $) -63
 Capital Exp. (TTM) (Millions $) 163

Qiagen N V

Qiagen N.V. is a biotech company that provides molecular diagnostics and life science research services.
The company develops and markets sample and assay technologies, including PCR, Sequencing, and Genomics, to customers in the academic research, pharma and biotech, healthcare, and environmental testing industries.
Qiagen Nv's products and services enable scientists to extract and process DNA, RNA, and other types of biological samples, perform gene expression analysis, and identify biomarkers for disease diagnosis and therapy.
Qiagen Nv was founded in 1984 and is headquartered in Venlo, Netherlands, with operations across the world.


   Company Address: Hulsterweg 82 Venlo 5912
   Company Phone Number:    Stock Exchange / Ticker: NYSE QGEN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
EVAX     
RGEN     
TECH     
TWST     
A     
BIO     
• View Complete Report
   



Business Update

QIAGEN Unveils Ambitious Expansion in Barcelona Pioneering the Future of Infectious Disease and Precision Medicine Te...

Published Fri, Nov 29 2024 3:07 AM UTC

QIAGEN Expands QIAstat-Dx Operations with New Advanced Facility in Barcelona to Propel Infectious Diseases and Precision Medicine Testing In a bold step to bolster its global presence in the cutting-edge realms of infectious diseases and precision medicine testing, QIAGEN has announced a remarkable expansion of its QIAstat-Dx operations in the Barcelona area. The company pla...

Business Update

QIAGEN Expands QIAstat-Dx Operations in Barcelona to Enhance Infectious Disease Testing Amid Revenue Challenges

Published Thu, Nov 28 2024 1:47 PM UTC

In a strategic move to bolster its standing in the infectious diseases and precision medicine sectors, QIAGEN N.V. has announced plans to relocate its QIAstat-Dx operations to a newly established facility in Esplugues de Llobregat, near Barcelona. This initiative, part of a long-term investment strategy, aims to enhance the company s capabilities in syndromic testing an esse...

Announcement

Pioneering Microbial Analysis Tools and Resilient Financial Performance QIAGEN Sets New Standards in Precision Diagno...

Published Wed, Nov 27 2024 9:05 PM UTC

As the landscape of molecular diagnostics continues to evolve, QIAGEN N.V. is making waves with the introduction of groundbreaking tools tailored for microbial analysis. The company s recent launch of customizable digital PCR assay design tools and advanced NGS panels marks a significant milestone in the realm of precision diagnostics. Revolutionizing Microbial Applications ...

Announcement

QIAGEN Bolsters Microbiome Research and Diagnostic Capabilities through Strategic Partnerships and FDA Approvals,

Published Tue, Nov 12 2024 9:06 PM UTC

QIAGEN Advances Microbiome and Diagnostic Research through Strategic Collaborations and Innovations VENLO, Netherlands. QIAGEN, a leader in molecular diagnostics and sample preparation technology, is making significant strides in both microbiome research and diagnostic testing through its collaboration with McGill University and ongoing expansion of its FDA-cleared test ...

Announcement

Reinvesting in Resilience QIAGEN?s Remarkable Q3 2024 Growth Amidst Client Revenue Declines,

Published Wed, Nov 6 2024 9:05 PM UTC

QIAGEN: A Strong Q3 2024 Performance Defies Market Trends In an era characterized by fluctuating market conditions and shifting consumer demands, QIAGEN N.V. has demonstrated remarkable resilience and adaptability. The company reported solid growth in the third quarter of 2024, exceeding analysts expectations while navigating challenges posed by a competitive landscape and...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com